Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps highlight key elements of the Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AML online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AML

Release Date: May 31, 2017
Expiration Date: May 31, 2018
Media: Internet - based


Activity Overview

Oncology Briefings™ is an online interactive monograph that will include a review of recent data regarding emerging treatments in patients with high-risk acute myeloid leukemia (AML), designed to aid physicians assessing and interpreting emerging data and novel therapeutic strategies and apply those findings to their practices. This format includes a brief presentation of clinical science, and features commentary by a national thought leader to provide key take home points and pearls for practice that will place the content into perspective. Audio sidebars will provide supporting evidence.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

CME Activity Table of Contents

  • Background and Disease Biology
  • Current Treatment Standards
  • Novel AML Therapies

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "Educational Content/Audio Files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational initiative is directed toward medical oncologists and hematologists who treat patients with AML. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of AML also are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Describe current treatment standards for the management of patients with AML
  2. Discuss novel AML therapies currently in clinical trials, with a focus on patients with high-risk AML, the greatest unmet need
  3. Explain recent efficacy and safety findings for novel AML therapies
  4. Review how the AML treatment paradigm might evolve with new clinical efficacy and safety findings, specifically for patients with high-risk AML, and discuss how new data sets may be applied to clinical practice

Faculty, Staff, and Planners' Disclosures


Harry P. Erba, MD, PhD
Professor of Medicine
Director, UAB Hematologic Malignancy Program
The University of Alabama at Birmingham School of Medicine
Birmingham, AL

Disclosure: Grant/Research Support: Agios, Amgen, Astellas Pharma, Celator, Daiichi Sankyo, ImmunoGen, Janssen, Juno Therapeutics, Millennium/Takeda, Seattle Genetics; Consultant: Amgen, Celator/Jazz Pharmaceuticals, Celgene, Daiichi Sankyo, ImmunoGen, Incyte, Millennium/Takeda, Novartis, Ono Pharmaceutical, Pfizer, Seattle Genetics, Sunesis; Speaker’s Bureau: Celgene, Incyte, Novartis; Other: GlycoMimetics (Chair, DSMB), Celgene (Chair, Scientific Steering Committee)

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By